Go Pro
→ Here’s the stock symbol I’ve promised (From Stansberry Research) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
$0.29
$0.35
$0.21
▼
$2.98
$4.16M1.21.24 million shs1.03 million shs
HIND
Vyome
$2.20
+1.9%		$2.18
$1.75
▼
$18.60
$15.16M1.4810,779 shs15,216 shs
OSR Holdings, Inc. stock logo
OSRH
OSR
$0.44
$0.39
$0.30
▼
$1.24
$15.56M0.56722,688 shs159,672 shs
Synlogic, Inc. stock logo
SYBX
Synlogic
$1.23
$0.78
$0.54
▼
$1.87
$15.07M0.4879,193 shs55,117 shs
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
0.00%+12.54%+0.85%-7.25%-88.57%
HIND
Vyome
0.00%+3.77%-2.22%+11.68%+219,999,900.00%
OSR Holdings, Inc. stock logo
OSRH
OSR
0.00%-1.12%+34.90%-21.98%-26.64%
Synlogic, Inc. stock logo
SYBX
Synlogic
0.00%+2.50%+73.00%+92.19%-12.14%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
$0.29
$0.35
$0.21
▼
$2.98
$4.16M1.21.24 million shs1.03 million shs
HIND
Vyome
$2.20
+1.9%		$2.18
$1.75
▼
$18.60
$15.16M1.4810,779 shs15,216 shs
OSR Holdings, Inc. stock logo
OSRH
OSR
$0.44
$0.39
$0.30
▼
$1.24
$15.56M0.56722,688 shs159,672 shs
Synlogic, Inc. stock logo
SYBX
Synlogic
$1.23
$0.78
$0.54
▼
$1.87
$15.07M0.4879,193 shs55,117 shs
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
0.00%+12.54%+0.85%-7.25%-88.57%
HIND
Vyome
0.00%+3.77%-2.22%+11.68%+219,999,900.00%
OSR Holdings, Inc. stock logo
OSRH
OSR
0.00%-1.12%+34.90%-21.98%-26.64%
Synlogic, Inc. stock logo
SYBX
Synlogic
0.00%+2.50%+73.00%+92.19%-12.14%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
3.00
Buy$9.003,053.47% Upside
HIND
Vyome
2.40
Hold$15.00581.82% Upside
OSR Holdings, Inc. stock logo
OSRH
OSR
1.00
SellN/AN/A
Synlogic, Inc. stock logo
SYBX
Synlogic
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest AIM, OSRH, HIND, and SYBX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/29/2026
HIND
Vyome
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
6/24/2026
OSR Holdings, Inc. stock logo
OSRH
OSR
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
6/1/2026
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
Ascendiant Capital Markets logo
Ascendiant Capital Markets
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$10.00 ➝ $9.00
(Data available from 8/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
$90K46.17N/AN/A($2.99) per share-0.10
HIND
Vyome
$320K48.26N/AN/A$0.67 per share3.28
OSR Holdings, Inc. stock logo
OSRH
OSR
$2.63M5.92N/AN/A$4.95 per share0.09
Synlogic, Inc. stock logo
SYBX
Synlogic
$8K1,883.28N/AN/A$1.09 per share1.13
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
-$13.96M-$24.68N/AN/AN/A-15,021.05%N/A-176.02%N/A
HIND
Vyome
-$10.26M-$12.27N/AN/AN/AN/A-203.92%-134.16%N/A
OSR Holdings, Inc. stock logo
OSRH
OSR
-$27.06M-$0.33N/AN/AN/A-363.26%-7.24%-5.41%N/A
Synlogic, Inc. stock logo
SYBX
Synlogic
-$23.36M-$0.06N/AN/AN/AN/A-26.47%-18.00%8/10/2026 (Estimated)

Latest AIM, OSRH, HIND, and SYBX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2026Q2 2026
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
N/A-$0.43N/A-$0.43N/A$0.03 million
5/15/2026Q1 2026
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
N/A-$0.69N/A-$0.69N/A$0.02 million
5/13/2026Q1 2026
OSR Holdings, Inc. stock logo
OSRH
OSR
N/A-$0.09N/A-$0.0880N/A$0.48 million
5/12/2026Q1 2026
HIND
Vyome
N/A-$0.15N/A-$0.15N/A$0.03 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
N/AN/AN/AN/AN/A
HIND
Vyome
N/AN/AN/AN/AN/A
OSR Holdings, Inc. stock logo
OSRH
OSR
N/AN/AN/AN/AN/A
Synlogic, Inc. stock logo
SYBX
Synlogic
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
0.10
1.01
1.01
HIND
Vyome
N/A
4.27
4.27
OSR Holdings, Inc. stock logo
OSRH
OSR
N/A
0.16
0.14
Synlogic, Inc. stock logo
SYBX
Synlogic
N/A
2.65
2.65

Institutional Ownership

CompanyInstitutional Ownership
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
12.02%
HIND
Vyome
22.06%
OSR Holdings, Inc. stock logo
OSRH
OSR
55.30%
Synlogic, Inc. stock logo
SYBX
Synlogic
63.40%

Insider Ownership

CompanyInsider Ownership
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
0.95%
HIND
Vyome
33.00%
OSR Holdings, Inc. stock logo
OSRH
OSR
36.90%
Synlogic, Inc. stock logo
SYBX
Synlogic
2.62%
CompanyEmployeesShares OutstandingFree FloatOptionable
AIM ImmunoTech Inc. stock logo
AIM
AIM ImmunoTech
2014.56 million14.43 millionNot Optionable
HIND
Vyome
507.02 million4.70 millionN/A
OSR Holdings, Inc. stock logo
OSRH
OSR
N/A35.12 million22.16 millionN/A
Synlogic, Inc. stock logo
SYBX
Synlogic
8012.25 million11.39 millionNo Data

Recent News About These Companies

Synlogic and Caldera Therapeutics announce merger and $278 million private placement
July 29, 2026  |  msn.comhttps://www.msn.com/en-us/health/other/synlogic-and-caldera-therapeutics-announce-merger-and-278-million-private-placement/ar-AA28Zdef
Synlogic and Caldera Therapeutics Announce Merger Agreement and Concurrent Private Placement
July 29, 2026  |  aol.comA
Synlogic's Strategic Crossroads: A Company in Limbo
February 10, 2026  |  aktiencheck.deA
Synlogic Challenges Nasdaq Delisting Notice
November 26, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/synlogic-challenges-nasdaq-delisting-notice?utm_source=marketbeat.com&utm_medium=referral
We Think Synlogic (NASDAQ:SYBX) Can Afford To Drive Business Growth
September 18, 2025  |  uk.finance.yahoo.comhttps://uk.finance.yahoo.com/news/think-synlogic-nasdaq-sybx-afford-105816457.html
Synlogic, Inc. (SYBX) Latest Stock News & Headlines - Yahoo Finance
June 28, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/quote/SYBX/news/
Synlogic's executive sells shares worth $2,802
February 5, 2025  |  msn.comhttps://www.msn.com/en-us/money/executive-leadership-and-management/synlogic-s-executive-sells-shares-worth-2-802/ar-AA1yq62c
Synlogic Reports Q3 2024 Financial Outcomes
November 14, 2024  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/synlogic-reports-q3-2024-financial-outcomes-1034015193
Synlogic, Inc.: Synlogic Reports Third Quarter 2024 Financial Results
November 13, 2024  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2024-11/63800545-synlogic-inc-synlogic-reports-third-quarter-2024-financial-results-399.htm
Synlogic Reports Third Quarter 2024 Financial Results
November 12, 2024  |  globenewswire.comhttps://www.globenewswire.com/news-release/2024/11/12/2979778/0/en/synlogic-reports-third-quarter-2024-financial-results.html
Synlogic preps phenylketonuria drug for phase 3 after mid-stage win
November 6, 2024  |  pharmaphorum.comP
Synlogic, Inc. (0A8U.L)
August 24, 2024  |  nz.finance.yahoo.comhttps://nz.finance.yahoo.com/quote/0A8U.L/news/
MIN.SG,0P0001I7V6,0 (MIN.SG)
August 16, 2024  |  nz.finance.yahoo.comhttps://nz.finance.yahoo.com/quote/MIN.SG/chart/
Maintaining Hold on Synlogic Amid Strategic Reassessment and Financial Uncertainty
August 14, 2024  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/maintaining-hold-on-synlogic-amid-strategic-reassessment-and-financial-uncertainty-1033683377
Synlogic, Inc.: Synlogic Reports Second Quarter 2024 Financial Results
August 8, 2024  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2024-08/62948190-synlogic-inc-synlogic-reports-second-quarter-2024-financial-results-399.htm
SYBX Stock Earnings: Synlogic Beats EPS for Q2 2024
August 8, 2024  |  investorplace.comhttps://investorplace.com/earning-results/2024/08/sybx-stock-earnings-synlogic-for-q2-of-2024/?cc=marketbeat&cp=pdtk
Synlogic Reports Second Quarter 2024 Financial Results
August 8, 2024  |  globenewswire.comhttps://www.globenewswire.com/news-release/2024/08/08/2926808/0/en/synlogic-reports-second-quarter-2024-financial-results.html
Synlogic Inc.
July 21, 2024  |  wsj.comhttps://www.wsj.com/market-data/quotes/SYBX
Synlogic Inc SYBX
July 21, 2024  |  morningstar.comM
The Summer Stock Exodus: 3 Companies to Ditch Before the Heat Hits
May 23, 2024  |  investorplace.comhttps://investorplace.com/2024/05/the-summer-stock-exodus-3-companies-to-ditch-before-the-heat-hits/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
AMD and Cerebras logos connected by glowing cables between server hardware racks in a data center.
AMD and Cerebras Create A New Blueprint For Hardware
By Jeffrey Neal Johnson | July 24, 2026
Microsoft logo surrounded by a glowing digital network graphic in a data center with screens displaying charts and code.
Microsoft Bets on In-House AI to Cut OpenAI and Anthropic Costs
By Chris Markoch | July 12, 2026
Delta Air Lines logo displayed over a close-up of the airline's aircraft fuselage, tail, and engine against a blue sky.
Delta Air Lines Lives Up to Its Claims: Shares Can Keep Climbing
By Thomas Hughes | July 12, 2026
Robotics components including a sensor module, circuit board, motors, and a mechanical joint arranged on a table.
3 Picks-and-Shovels Stocks Powering the Humanoid Robotics Buildout
By Ryan Hasson | July 17, 2026
Technicians in AST SpaceMobile gear prepare a satellite and payload fairing in a hangar as a rocket stands on the launch pad outside.
Is Buying a Launch Company AST SpaceMobile’s Next Vertical Integration Move?
By Jessica Mitacek | July 23, 2026
AIM ImmunoTech stock logo

AIM ImmunoTech NYSEAMERICAN:AIM

$0.29 0.00 (0.00%)
Closing price 08/7/2026 04:10 PM Eastern
Extended Trading
$0.28 -0.01 (-2.59%)
As of 08/7/2026 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente; Jubilant HollisterStier; Sterling Pharma Solutions; Erasmus University Medical Center Rotterdam; Azenova, LLC; and Alcami Corporation. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.

Vyome NASDAQ:HIND

$2.20 +0.04 (+1.85%)
Closing price 08/7/2026 03:57 PM Eastern
Extended Trading
$2.15 -0.05 (-2.23%)
As of 08/7/2026 07:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy; and ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without cutting or permanently removing portions of the stomach, or bypassing any portion of the gastrointestinal tract. It also offers ReShapeCare virtual health coaching program, a virtual telehealth weight management program that supports healthy lifestyle changes for all medically managed weight-loss patients; and ReShape Diabetes Bloc-Stim Neuromodulation, a technology that is in preclinical development for the treatment of type 2 diabetes mellitus. In addition, the company provides Obalon Balloon System, a swallowable capsule used to track and display the location of the balloon during placement. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in San Clemente, California.

OSR stock logo

OSR NASDAQ:OSRH

$0.44 0.00 (0.00%)
Closing price 08/7/2026 03:59 PM Eastern
Extended Trading
$0.45 +0.01 (+2.26%)
As of 08/7/2026 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

OSR Holdings leverages its international network of partners in the US, Europe, and South Korea to market and license its pipeline of proprietary platform technologies for broad application to efficient clinical trial programs, with the ultimate goal of addressing unmet medical needs. We partner with biotherapeutics companies with innovative and proprietary drug R&D "platform technologies" versus "assets only" companies, whose commercial viability is heavily dependent on positive results for individual treatment modalities in extremely rigorous and time consuming clinical trials. We focus on value creation through investments and collaborations with US and EU biotech companies, with the strategic goal of expansion into South Korea (specifically) and Asia (generally). OSR Holdings is headquartered in Paju, South Korea.

Synlogic stock logo

Synlogic NASDAQ:SYBX

$1.23 0.00 (0.00%)
As of 08/7/2026 01:40 PM Eastern

Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas